Update summarising the conclusions of the international consultation on male lower urinary tract symptoms

摘要

The International Consultation on Urological Disease have recently published comprehensive conclusions,based on evidence reviewed by eight committees,on aspects of male lower urinary tract symptoms(LUTS).In this review,we summarise the conclusions from four of the committees,namely,the evidence regarding the epidemiology of male LUTS,patient assessment,nocturia and medical management.It is indisputable that with an expanding and ageing global population the prevalence of male LUTS is likely to increase.Therefore symptom prevention and preservation of quality of life(QoL)feature highly in the guidelines.There are now a number of different medical options,proven to lead to significant improvements in symptom scores,flow rate and QoL available to men with LUTS.Metaanalyses have shown the benefits for alpha blockers,antimuscarinics,5-αreductase and phosphodiesterase-5 inhibitors.High level evidence also exists for combinations of all of the above with alpha blockers and so men with concomitant storage symptoms,prostate volume>30 mL,PSA>1.4 or erectile dysfunction may be considered for combination treatment of an alpha blocker with an antimuscarinic,5-αreductase inhibitor or phosphodiesterase-5 inhibitor respectively.In an era of personalised medicine,appropriate patient selection is likely to provide the key to the most effective clinical management strategy.